Form 4: Director Prins Exercises, Sells AMPH Stock

Amphastar Pharmaceuticals Director Richard K. Prins exercised stock options and subsequently sold 4,179 shares of common stock on November 25, 2025.

Summary

• Richard K. Prins, a Director of Amphastar Pharmaceuticals, Inc. (AMPH), engaged in two transactions on November 25, 2025.
• Prins exercised stock options to acquire 4,179 shares of common stock at an exercise price of $16.69 per share.
• Immediately following the exercise, Prins sold all 4,179 shares of common stock at a weighted average price of $27.1006 per share.
• The sale price ranged from $27.10 to $27.125 per share.
• After these transactions, Prins beneficially owns 35,183 shares of Amphastar Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine insider filing (Form 4) involving the exercise of options and subsequent sale of shares, likely for tax or liquidity purposes. It doesn't inherently signal strong positive or negative sentiment about the company's future prospects, though the director is realizing a profit.

Positives

• The exercise of options indicates a director realizing value from their compensation, which can be seen as a positive for the individual.
• The sale price of $27.1006 per share is significantly higher than the exercise price of $16.69, indicating a profitable transaction for the director.

Negatives

• The sale of shares by a director, even if for option exercise and tax purposes, reduces their direct ownership stake in the company.

Future Outlook

NA

Industry Context

This Form 4 filing reflects routine insider transaction activity, common across all industries, where executives and directors manage their equity compensation. It does not provide specific insights into Amphastar Pharmaceuticals' operational performance or industry trends.

Related Party Transactions

• Director Richard K. Prins, a related party, exercised stock options and sold shares of Amphastar Pharmaceuticals, Inc. common stock.

Stakeholder Impact

• Shareholders may observe a slight reduction in direct insider ownership, though the transaction is routine and often pre-planned, minimizing significant impact.
• The transaction demonstrates a director realizing value from their equity compensation.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where a director exercised stock options and immediately sold the acquired shares. Such transactions are common for liquidity or tax planning and do not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. The director still retains a significant number of shares.

Keywords

Amphastar Pharmaceuticals, AMPH, Form 4, Insider Trading, Stock Option Exercise, Director Stock Sale, Richard K. Prins, Beneficial Ownership